These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 18079601)
1. [Practical clinical use of therapeutic agents for Alzheimer's disease]. Arai T Nihon Yakurigaku Zasshi; 2007 Dec; 130(6):494-8. PubMed ID: 18079601 [No Abstract] [Full Text] [Related]
2. Drugs for cognitive loss and dementia. Treat Guidel Med Lett; 2013 Oct; 11(134):95-100; quiz 1 p following p100.. PubMed ID: 24081314 [TBL] [Abstract][Full Text] [Related]
4. Combination therapy no advantage in Alzheimer's treatment. Harv Health Lett; 2012 Jun; 37(8):8. PubMed ID: 22774260 [No Abstract] [Full Text] [Related]
5. Discontinuing donepezil or starting memantine for Alzheimer's disease. Schneider LS N Engl J Med; 2012 Mar; 366(10):957-9. PubMed ID: 22397659 [No Abstract] [Full Text] [Related]
6. Discontinuing donepezil or starting memantine for Alzheimer's disease. Suzuki T N Engl J Med; 2012 Jun; 366(23):2227-8; author reply 2228. PubMed ID: 22670911 [No Abstract] [Full Text] [Related]
7. Alzheimer's disease: will advances made in the past turn the tide? Semla TP Ann Pharmacother; 2007 Sep; 41(9):1494-6. PubMed ID: 17666576 [No Abstract] [Full Text] [Related]
8. Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease. Waldemar G; Hyvärinen M; Josiassen MK; Kørner A; Lehto H; Wetterberg P Int J Geriatr Psychiatry; 2008 Sep; 23(9):979-81. PubMed ID: 18229874 [No Abstract] [Full Text] [Related]
10. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention. Beier MT Pharmacotherapy; 2007 Mar; 27(3):399-411. PubMed ID: 17316151 [TBL] [Abstract][Full Text] [Related]
11. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease. Grossberg GT; Edwards KR; Zhao Q J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811 [TBL] [Abstract][Full Text] [Related]
12. [Mechanisms of action of Alzheimer medications]. Alhainen K Duodecim; 2003; 119(20):1959-66. PubMed ID: 14640001 [No Abstract] [Full Text] [Related]
13. NMDA receptor antagonists. A new therapeutic approach for Alzheimer's disease. Farlow MR Geriatrics; 2004 Jun; 59(6):22-7. PubMed ID: 15224791 [TBL] [Abstract][Full Text] [Related]
14. Discontinuing donepezil or starting memantine for Alzheimer's disease. Finucane MM; Finucane TE N Engl J Med; 2012 Jun; 366(23):2227-8; author reply 2228. PubMed ID: 22670912 [No Abstract] [Full Text] [Related]
15. Discontinuing Alzheimer's disease drug therapy: why, when, and how. Crutchfield D Director; 2008; 16(1):19-21. PubMed ID: 19343870 [TBL] [Abstract][Full Text] [Related]
16. Cessation of donepezil is associated with clinical decline in patients with moderate-to-severe Alzheimer's disease compared to continuation of donepezil or addition or substitution of memantine. Tariot PN Evid Based Med; 2013 Apr; 18(2):62-3. PubMed ID: 22736656 [No Abstract] [Full Text] [Related]
17. Pharmacotherapeutic strategies in the treatment of severe Alzheimer's disease. Deardorff WJ; Grossberg GT Expert Opin Pharmacother; 2016 Sep; 17(13):1789-800. PubMed ID: 27450461 [TBL] [Abstract][Full Text] [Related]
18. New drugs for Alzheimer's disease in Japan. Takeda M; Tanaka T; Okochi M Psychiatry Clin Neurosci; 2011 Aug; 65(5):399-404. PubMed ID: 21851448 [No Abstract] [Full Text] [Related]